Zheng Quan Shi Bao Wang·2026-01-12 14:27Core Viewpoint - Wanbangde and Haixiang Pharmaceutical have agreed to collaborate on the development of WP205 for the treatment of Amyotrophic Lateral Sclerosis (ALS), leveraging their respective strengths to achieve regulatory approval and commercialization in major global markets [1][2]. Group 1: Collaboration Details - The collaboration involves Wanbangde's subsidiary, Wanbangde Pharmaceutical, and Haixiang Pharmaceutical, focusing on the R&D and commercialization of the WP205 product, which has received orphan drug designation from the FDA [1][2]. - Haixiang Pharmaceutical will provide a total funding of 150 million yuan for the collaboration, while Wanbangde will be responsible for the R&D and commercialization efforts [3][4]. Group 2: Financial and Regulatory Aspects - The orphan drug designation from the FDA offers various incentives, including tax credits for clinical trial costs and a seven-year market exclusivity post-approval, which will benefit Wanbangde in the development and commercialization of WP205 [3]. - Haixiang Pharmaceutical will receive 15% of the commercialization profits from WP205, whether through direct sales, licensing, or third-party sales [3][4]. Group 3: Strategic Implications - The collaboration is expected to enhance Haixiang Pharmaceutical's position in the peptide drug sector and contribute positively to its innovation and market competitiveness [4]. - Wanbangde views this partnership as a strategic win-win, aiming to accelerate the transition of WP205 from preclinical research to clinical application [4].